ARTICLE | Regulation
Slippery slope
How NICE breaks new ground linking price of Soliris to Alexion's R&D investment
March 17, 2014 7:00 AM UTC
The U.K.'s National Institute for Health and Care Excellence is breaking new ground by seeking to link the price of Soliris eculizumab to Alexion Pharmaceuticals Inc.'s R&D investment in the Orphan drug; the question is whether the biotech will be able to reach a reimbursement deal without crossing that Rubicon.
Presented with an outstanding clinical efficacy data package and without a cost-effectiveness evaluation to poke holes in, NICE appears to be reaching for a new hammer to beat down the price of Soliris, which in itself is not surprising...